好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Subacute-onset Progressive Supranuclear Palsy-like Syndrome with Positive Anti-glycine Antibodies
Movement Disorders
P7 - Poster Session 7 (8:00 AM-9:00 AM)
17-012

To report two cases of anti-glycine antibody-positive syndromes mimicking progressive supranuclear palsy (PSP) and to emphasize the role of autoimmune antibodies in movement disorders.

Autoimmune movement disorders comprise treatable and possibly reversible conditions. Over the years, a growing number of autoimmune syndromes with a multifaceted and ever-expending phenotype has been described. 

We describe two patients with a constellation of symptoms closely resembling PSP who were found to have positive anti-glycine antibodies

We describe a patient with neuropsychiatric symptoms, eyelid-opening apraxia, vertical gaze restriction, severe axial rigidity, and frequent falls developing over six months. Our diagnostic tests revealed positive serum anti-glycine antibodies, although he was only mildly responsive to immunotherapy. The second patient experienced progressive gait dysfunction with unilateral weakness who further developed vertical gaze restriction, severe rigidity, and apraxia. Her workup also revealed positive serum anti-glycine antibodies and she experienced a mild improvement with plasmapheresis, maintenance therapy intravenous immunoglobulins, and rituximab.

Anti-glycine antibody syndromes take on a broad syndromic spectrum, which includes stiff person syndrome, progressive encephalomyelitis, and epilepsy. We propose our cases may expand the spectrum of anti-glycine autoimmune phenotypes. At the same time, we underscore the existence of autoantibodies of unknown significance and the growing need for accurate biomarkers to differentiate autoimmune from neurodegenerative disorders.

Authors/Disclosures
Mattia Rosso, MD (Medical University of South Carolina)
PRESENTER
Dr. Rosso has nothing to disclose.
Danielle A. Reynolds, MD (Yale New Haven Hospital) Dr. Reynolds has nothing to disclose.
Lindsay S. McAlpine, MD (Yale University) Dr. McAlpine has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Law Firm. The institution of Dr. McAlpine has received research support from NIH.
Carolyn Fredericks, MD (Yale School of Medicine, Department of Neurology) The institution of Dr. Fredericks has received research support from Alzheimer's Association. The institution of Dr. Fredericks has received research support from National Institute on Aging.
Veronica E. Santini, MD, MA, FAAN Dr. Santini has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scion NeuroStim, Inc. The institution of Dr. Santini has received research support from MeiraGTx, LLC. The institution of Dr. Santini has received research support from Ono Pharmaceuticals. The institution of Dr. Santini has received research support from Lundbeck. The institution of Dr. Santini has received research support from American Parkinson Disease Association. The institution of Dr. Santini has received research support from Mission MSA. The institution of Dr. Santini has received research support from CurePSP. The institution of Dr. Santini has received research support from Parkinson Foundation. Dr. Santini has received personal compensation in the range of $500-$4,999 for serving as a course director and for committee responsibilities with 好色先生. Dr. Santini has received personal compensation in the range of $500-$4,999 for serving as a course director and for committee responsibilities with International Parkinson and Movement Disorders Society. Dr. Santini has received personal compensation in the range of $0-$499 for serving as a invited speaker with Parkinson Study Group. Dr. Santini has received personal compensation in the range of $500-$4,999 for serving as a data safety monitoring board with NIH.